Hexima Limited (HXL.XA)

0.0220 0.0000 (0.00%) At close: 02:29PM AEDT

Hexima Limited

La Trobe Institute for Molecular Science
Level 4 LIMS2 La Trobe University
Bundoora, VIC 3086
Australia
61 3 9479 1210
https://hexima.com.au

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Helen Molloy	Financial Controller	224.24k	N/A	N/A
Prof. Marilyn A. Anderson A.O., AO, B.Sc., BSc (Hons), FAA, FAICD, FT	Chief Science Officer	48.63k	N/A	1951
Dr. Nancy Sacco	Chief Development Officer	175.25k	N/A	N/A
Mr. Geoffrey Paul Kempler B.Sc.	MD & Chairman	N/A	N/A	1955
Dr. Neil Forrester	Vice President of Business Development	N/A	N/A	N/A
Ms. Leanne Ralph	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia. The company's lead drug candidate is the pezadeftide, which has completed phase II clinical trials for the treatment of onychomycosis. Hexima Limited was incorporated in 1997 and is headquartered in Bundoora, Australia.

Corporate governance

Hexima Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.